Navigation Links
Not All Epilepsy Drugs Raise Suicide Risk: Study
Date:7/26/2010

By Madonna Behen
HealthDay Reporter

MONDAY, July 26 (HealthDay News) --Since 2008, the U.S. Food and Drug Administration has required that all epilepsy drugs bear a warning label about an increased risk of suicidal behaviors, but German doctors report that only certain medications may increase the risk of self-harm.

However, some epilepsy researchers are skeptical of the findings and say the paper raises more questions than it answers.

The study of more than 44,000 epilepsy patients in the United Kingdom revealed that those who took relatively new antiepileptic drugs with a higher risk of causing depression, such as levetiracetam (Keppra), topiramate (Topamax) and vigabatrin (Sabril), were three times more likely to harm themselves or attempt suicide than those who weren't taking any epilepsy medications.

The researchers found that patients who took conventional epilepsy medications, such as divalproex (Depakote, Depakote ER, Depakene) or phenytoin (Dilantin), or newer drugs with a low risk of depression, such as gabapentin (Neurontin) or lamotrigine (Lamictal), faced no increased risk of self-harm of suicidal behavior.

"These potential adverse effects should be considered in the selection of antiepileptics and during monitoring of the effects of these medications in epilepsy patients," said study author Dr. Frank Andersohn, of the Medical Center in Berlin. "Patients with epilepsy who are currently taking an antiepileptic drug that might increase the risk of depression and/or suicidal behavior should, however, not abruptly stop or change their medication but should discuss this issue with their physician."

Andersohn and his colleagues examined data on 44,300 patients in the United Kingdom General Practice Research Database who had epilepsy and had at least one prescription for an epilepsy drug from 1989 through 2005. Participants were followed for an average of five-and-a-half years. During that time, 453 patients had harmed themselves or attempted suicide, and 78 people died at the time or within four weeks of the initial attempt. The 453 patients were compared with 8,962 others who had not harmed themselves or attempted suicide. Six of the 453 people, or 1.3 percent, who harmed themselves or attempted suicide were taking the newer drugs with the higher risk of depression, compared with 45 of the 8,962 people, or 0.5 percent, of those who didn't harm themselves.

The findings were published in the July 27 issue of Neurology.

An accompanying editorial notes several weaknesses of the study. For one thing, the results were based on a very small number of cases. Also, those taking the newer drugs with the higher risk of depression may have been more likely to have chronic and severe epilepsy, and these patients are known to have a higher risk of suicide, noted the editorial authors.

The FDA added the suicide warning to epilepsy drugs after an agency review of 199 studies found that patients taking the drugs had about twice the risk of suicidal behavior compared with patients taking a placebo. The absolute risk amounted to about one added case of suicidal thoughts or behaviors for every 500 patients taking the antiepileptic drugs vs. placebo.

Dr. Josemir Sander, co-author of the editorial, said he doubted these new findings would prompt doctors to reconsider what drugs they prescribe. "I think that most physicians will use good sense and see that there are far too many problems with [the study] and not make knee-jerk reactions," said Sander, of the University College London's Institute of Neurology.

One expert agreed that the findings are far from conclusive. "Although some antiepileptic drugs may pose a risk to increasing suicidal behavior, this study does not prove that," said Dr. Orrin Devinsky, director of the New York University Comprehensive Epilepsy Center. "However, it strongly speaks to the need for more information."

Devinsky added that it's important to consider the real risks of epilepsy vs. a possible small increased risk of suicide. "Epilepsy can be a progressive and deadly disorder, especially for those with chronic and severe seizures. The dangers of epilepsy far exceed the dangers of the possible small increase in suicidal behavior risk from some medications."

More information

To learn about epilepsy, visit the Epilepsy Foundation.

SOURCES: Frank Andersohn, M.D., Institute for Social Medicine, Epidemiology and Health Economics, Charite University Medical Center, Berlin, Germany; Josemir Sander, M.D., Ph.D., professor, University College London Institute of Neurology, and National Hospital for Neurology and Neurosurgery, London, England, and the Epilepsy Institute of the Netherlands Foundation, the Netherlands; Orrin Devinsky, M.D., director, Epilepsy Center, New York University Langone Medical Center, and professor, neurology, neurosurgery and psychiatry, New York University School of Medicine; July 27, 2010, Neurology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Brain Injury May Raise Soldiers Epilepsy Risk
2. FDA accepts historical controls for epilepsy monotherapy studies
3. Study confirms favorable long-term prognosis of epilepsy
4. Children With Epilepsy Feel on Par With Healthy Siblings
5. Altered brain development found in children with newly diagnosed epilepsy
6. University Hospitals Neurological Institute hosts international epilepsy colloquium
7. Children with epilepsy say their quality of life is better than their parents think
8. Gene Mutation Ups Risk of Sudden Death in People with Epilepsy
9. Fetal alcohol spectrum disorder linked to high prevalence of epilepsy, Queens study
10. Purple Day March 26th: The United States Goes Purple in Support of Epilepsy Awareness
11. Implant Shows Promise for Hard-to-Treat Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Not All Epilepsy Drugs Raise Suicide Risk: Study
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology: